Overview
Signal transduction
Signal transduction and cancer
Signal transduction inhibitors (STIs)
Multi-signal transduction regulators (STRs)
Phenoxodiol
|
|
Multi-signal transduction regulators (MSTRs)
MEI believes that this approach represents the most promising approach to universally effective and safe anti-cancer therapy.
Multi-signal transduction regulators (MSTRs) differs from signal transduction inhibitors (STIs) in two key areas.
- First, STIs generally are designed to block a single malfunctioning target within the cell, whereas
| MSTRs are designed to hit multiple malfunctioning targets, thereby increasing the likelihood of blocking the cancer process. |
- Second, STIs are based on the notion that malfunctions in cancer cells are due to over-expression of certain key checkpoints. Therefore, STIs aim to inhibit or block that over-expression.
Signal transduction regulation recognizes the fact that malfunctions in cancer cells are as much about under-expressing as they are about over-expressing checkpoints. That is, blocking cancer cells requires some checkpoints to be blocked and others to be activated.
| MSTRs have the ability of both blocking over-reacting pathways as well as restoring activity to under-performing pathways. |
|
